• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

    4/11/24 10:01:51 AM ET
    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance
    Get the next $ALPN alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.

    Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday’s session.

    Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.

    Enliven Therapeutics shares surged 26% to $24.97 on Thursday.

    Here are some other big stocks recording losses in today’s session.

    • Rallybio Corporation (NASDAQ:RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
    • Alpine Immune Sciences, Inc. (NASDAQ:ALPN) jumped 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
    • Janux Therapeutics, Inc. (NASDAQ:JANX) shares jumped 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) rose 14.6% to $15.91.
    • AnaptysBio, Inc. (NASDAQ:ANAB) rose 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
    • Fiverr International Ltd. (NYSE:FVRR) gained 10.5% to $21.25 after the company's board authorized a $100 million share repurchase program.
    • GigaCloud Technology Inc. (NASDAQ:GCT) shares jumped 10.2% to $34.18.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) climbed 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
    • AlTi Global, Inc. (NASDAQ:ALTI) gained 9.3% to $5.06.
    • Nexxen International Ltd. (NASDAQ:NEXN) rose 7.3% to $5.62.
    • StepStone Group LP (NASDAQ:STEP) gained 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.
    • Frontline plc (NYSE:FRO) rose 5.9% to $24.47.
    • IAMGOLD Corporation (NYSE:IAG) gained 3.6% to $3.74.

     

    Now Read This: Dell, Designer Brands And 2 Other Stocks Insiders Are Selling

    Get the next $ALPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPN
    $ALTI
    $ANAB
    $ELVN

    CompanyDatePrice TargetRatingAnalyst
    StepStone Group Inc.
    $STEP
    4/3/2026$60.00Buy
    UBS
    StepStone Group Inc.
    $STEP
    4/2/2026$60.00Buy
    UBS
    Fiverr International Ltd.
    $FVRR
    3/2/2026Buy → Neutral
    BTIG Research
    StepStone Group Inc.
    $STEP
    3/2/2026$55.00Equal Weight → Overweight
    Barclays
    Fiverr International Ltd.
    $FVRR
    2/19/2026$15.00Overweight → Neutral
    Analyst
    Fiverr International Ltd.
    $FVRR
    2/19/2026$14.00Buy → Neutral
    Roth Capital
    Fiverr International Ltd.
    $FVRR
    2/18/2026Buy → Hold
    Needham
    Frontline Plc
    $FRO
    1/12/2026Neutral → Buy
    Clarksons Platou
    More analyst ratings

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mitchell Steven R bought $565,772 worth of shares (12,793 units at $44.23) (SEC Form 4)

    4 - StepStone Group Inc. (0001796022) (Issuer)

    2/25/26 4:46:56 PM ET
    $STEP
    Investment Managers
    Finance

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/2/25 6:17:02 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on StepStone Group with a new price target

    UBS initiated coverage of StepStone Group with a rating of Buy and set a new price target of $60.00

    4/3/26 10:44:59 AM ET
    $STEP
    Investment Managers
    Finance

    UBS initiated coverage on StepStone Group with a new price target

    UBS initiated coverage of StepStone Group with a rating of Buy and set a new price target of $60.00

    4/2/26 8:12:43 AM ET
    $STEP
    Investment Managers
    Finance

    Fiverr downgraded by BTIG Research

    BTIG Research downgraded Fiverr from Buy to Neutral

    3/2/26 8:54:59 AM ET
    $FVRR
    Real Estate

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by AlTi Global Inc.

    SCHEDULE 13D/A - AlTi Global, Inc. (0001838615) (Subject)

    4/2/26 12:15:50 PM ET
    $ALTI
    Investment Managers
    Finance

    SEC Form 6-K filed by Iamgold Corporation

    6-K - IAMGOLD CORP (0001203464) (Filer)

    4/2/26 8:02:55 AM ET
    $IAG
    Precious Metals
    Basic Materials

    SEC Form 6-K filed by Iamgold Corporation

    6-K - IAMGOLD CORP (0001203464) (Filer)

    4/2/26 8:00:30 AM ET
    $IAG
    Precious Metals
    Basic Materials

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moonbounce Launches with $12M to Give Organizations Real-Time Control Over AI Behavior

    Former Meta trust & safety lead introduces a new standard for predictable, compliant generative AI Moonbounce, the AI control engine that ensures systems behave exactly as designed at any scale, today launched with $12 million in funding. Lead investors include Amplify Partners and StepStone Group (NASDAQ:STEP), with participation from angel investors PrimeSet and Josh Leslie, former CEO of Cumulus Networks and Gremlin. As generative AI scales across industries, traditional content moderation approaches based on retroactive review, rigid policies, and manual oversight cannot keep pace with systems that are making thousands of decisions per second. Operational, reputational, and regulato

    4/3/26 12:04:00 PM ET
    $STEP
    Investment Managers
    Finance

    Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. "This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnersh

    4/1/26 8:01:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nexxen Announces March 2026 Share Repurchase Program Summary

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ:NEXN) ("Nexxen" or the "Company"), the advertising technology platform powered by unique data and media, today announced that it repurchased 224,229 shares at an average price of $7.10 during March 2026 and had 56,876,930 shares outstanding (excluding treasury shares) as of March 31, 2026. This monthly report reflects the completion of the Company's $20 million repurchase program. As a result, the Company does not intend to issue monthly reports in the future about its repurchase activities, which were issued in connection with Nexxen's prior AIM listing requirements. In connection with the Company's new repurc

    4/1/26 8:00:00 AM ET
    $NEXN
    Computer Software: Programming Data Processing
    Technology

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gray Susannah

    3 - ANAPTYSBIO, INC (0001370053) (Issuer)

    4/3/26 4:00:54 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Harrington Michael W

    4 - AlTi Global, Inc. (0001838615) (Issuer)

    4/2/26 8:19:18 PM ET
    $ALTI
    Investment Managers
    Finance

    SEC Form 4 filed by Moran Kevin P.

    4 - AlTi Global, Inc. (0001838615) (Issuer)

    4/2/26 8:16:19 PM ET
    $ALTI
    Investment Managers
    Finance

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Leadership Updates

    Live Leadership Updates

    View All

    AlTi Global, Inc. Announces CEO Transition, Appoints Nancy Curtin as Interim Chief Executive Officer

    AlTi Global, Inc. (NASDAQ:ALTI) ("AlTi" or the "Company"), a leading independent global wealth manager with $93 billion in assets, today announced that Nancy Curtin has been appointed Interim Chief Executive Officer of AlTi and to its Board of Directors, effective immediately. Ms. Curtin is a member of the executive leadership team and serves as Global Chief Investment Officer of AlTi. She succeeds Michael Tiedemann, who will remain available in an advisory capacity to support the transition. "On behalf of the Board, I want to thank Mike for his many years of dedicated leadership," said Timothy Keaney, Chair of the Board. "Mike's vision and commitment have been instrumental in building th

    3/31/26 7:00:00 AM ET
    $ALTI
    Investment Managers
    Finance

    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

    Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Financials

    Live finance-specific insights

    View All

    AlTi Global, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    AlTi Global, Inc. (NASDAQ:ALTI) ("AlTi" or the "Company"), a leading independent global wealth manager with $93 billion in assets, today announced financial results for the fourth quarter and full year ended December 31, 2025. A presentation of the Company's results for the fourth quarter and full year ended December 31, 2025 can be found on the Events & Presentations section of the AlTi investor relations website. Webcast and Earnings Conference Call Management will host a webcast and conference call on Tuesday, March 31, 2026, at 8:30 a.m. ET to provide a business update and discuss the financial results for the quarter and year. The call can be accessed by dialing (877) 704-4453 (d

    3/31/26 7:01:00 AM ET
    $ALTI
    Investment Managers
    Finance

    AlTi Global, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results

    AlTi Global, Inc. (NASDAQ:ALTI) ("AlTi" or the "Company"), a leading independent global wealth manager with $89 billion in assets, today announced it will release its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 31, 2026. Management will host a conference call and webcast the same day at 8:30 a.m. Eastern Time to provide a business update and discuss the financial results for the quarter and year. Conference Call Information Participants are invited to access the conference call by dialing one of the following numbers when prompted: Domestic: 1-877-704-4453 International: 1-201-389-0920 Alternatively, participants can reg

    3/19/26 5:00:00 PM ET
    $ALTI
    Investment Managers
    Finance

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026 Alignment with China's Center for Drug Evaluation (CDE) on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application (NDA) submission for conditional approval expected in the first half of 2026 Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis (PD) trial(272 patients acros

    3/12/26 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by StepStone Group Inc.

    SC 13D/A - StepStone Group Inc. (0001796022) (Subject)

    12/5/24 7:16:56 PM ET
    $STEP
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by StepStone Group Inc.

    SC 13D/A - StepStone Group Inc. (0001796022) (Subject)

    11/21/24 4:54:57 PM ET
    $STEP
    Investment Managers
    Finance

    $ALPN
    $ALTI
    $ANAB
    $ELVN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at AlTi Global Inc. on Jun 5

    On June 5, 2024, **Tiedemann Michael** made a significant purchase of **47,373** units of **AlTi Global Inc.** shares at a price of **$4.86** per share, amounting to a total investment of **$230,460**. This transaction led to a **10%** increase in his direct ownership of the company's shares, bringing his total holding to **499,887** units. This insider purchase was disclosed in the **SEC Form 4** filing. Interestingly, this purchase follows a series of other notable transactions by **Tiedemann Michael** in the past month. On May 21, 2024, he acquired **100,000** units of shares at **$4.61** each, increasing his direct ownership by **32%** to **409,146** units. Just two days later, on May 23

    6/10/24 1:07:48 AM ET
    $ALTI
    Investment Managers
    Finance